ONTRUZANT (trastuzumab-dttb)


ONTRUZANT (trastuzumab-dttb)

  • HER-2 (+) adenocarcinoma of gastroesophageal junction
  • HER-2 positive gastric adenocarcinoma
  • HER2 positive breast cancer